Article

Stem cell therapy for ischemic heart disease.

Department of Medicine, University of Minnesota Medical School , Minneapolis, Minnesota 55455, USA.
Antioxidants & Redox Signaling (impact factor: 8.2). 12/2010; 13(12):1879-97. DOI:10.1089/ars.2010.3434 pp.1879-97
Source: PubMed

ABSTRACT Stem cell transplantation has emerged as a novel treatment option for ischemic heart disease. Different cell types have been utilized and the recent development of induced pluripotent stem cells has generated tremendous excitement in the regenerative field. Bone marrow-derived multipotent progenitor cell transplantation in preclinical large animal models of postinfarction left ventricular remodeling has demonstrated long-term functional and bioenergetic improvement. These beneficial effects are observed despite no significant engraftment of bone marrow cells in the myocardium and even lower differentiation of these cells into cardiomyocytes. It is thought to be related to the paracrine effect of these stem cells, which secrete factors that lead to long-term gene expression changes in the host myocardium, thereby promoting neovascularization, inhibiting apoptosis, and stimulating resident cardiac progenitor cells. Future studies are warranted to examine the changes in the recipient myocardium after stem cell transplantation and to investigate the signaling pathways involved in these effects.

0 0
 · 
0 Bookmarks
 · 
5 Views
  • Source
    Article: Safe genetic modification of cardiac stem cells using a site-specific integration technique.
    Feng Lan, Junwei Liu, Kazim H Narsinh, Shijun Hu, Leng Han, Andrew S Lee, Marisa Karow, Patricia K Nguyen, Divya Nag, Michele P Calos, Robert C Robbins, Joseph C Wu
    [show abstract] [hide abstract]
    ABSTRACT: Human cardiac progenitor cells (hCPCs) are a promising cell source for regenerative repair after myocardial infarction. Exploitation of their full therapeutic potential may require stable genetic modification of the cells ex vivo. Safe genetic engineering of stem cells, using facile methods for site-specific integration of transgenes into known genomic contexts, would significantly enhance the overall safety and efficacy of cellular therapy in a variety of clinical contexts. We used the phiC31 site-specific recombinase to achieve targeted integration of a triple fusion reporter gene into a known chromosomal context in hCPCs and human endothelial cells. Stable expression of the reporter gene from its unique chromosomal integration site resulted in no discernible genomic instability or adverse changes in cell phenotype. Namely, phiC31-modified hCPCs were unchanged in their differentiation propensity, cellular proliferative rate, and global gene expression profile when compared with unaltered control hCPCs. Expression of the triple fusion reporter gene enabled multimodal assessment of cell fate in vitro and in vivo using fluorescence microscopy, bioluminescence imaging, and positron emission tomography. Intramyocardial transplantation of genetically modified hCPCs resulted in significant improvement in myocardial function 2 weeks after cell delivery, as assessed by echocardiography (P=0.002) and MRI (P=0.001). We also demonstrated the feasibility and therapeutic efficacy of genetically modifying differentiated human endothelial cells, which enhanced hind limb perfusion (P<0.05 at day 7 and 14 after transplantation) on laser Doppler imaging. The phiC31 integrase genomic modification system is a safe, efficient tool to enable site-specific integration of reporter transgenes in progenitor and differentiated cell types.
    Circulation 09/2012; 126(11 Suppl 1):S20-8. · 14.74 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

bioenergetic improvement
 
bone marrow cells
 
Bone marrow-derived multipotent progenitor cell transplantation
 
cell transplantation
 
Different cell types
 
Future studies
 
induced pluripotent
 
inhibiting apoptosis
 
ischemic heart disease
 
long-term functional
 
long-term gene expression changes
 
preclinical large animal models
 
recent development
 
secrete factors
 
signaling pathways
 
significant engraftment
 
Stem cell transplantation
 
stem cells
 
stimulating resident cardiac progenitor cells
 
tremendous excitement
 

Mohammad Nurulqadr Jameel